AR002976A1 - Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas - Google Patents

Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas

Info

Publication number
AR002976A1
AR002976A1 ARP960101937A AR10193796A AR002976A1 AR 002976 A1 AR002976 A1 AR 002976A1 AR P960101937 A ARP960101937 A AR P960101937A AR 10193796 A AR10193796 A AR 10193796A AR 002976 A1 AR002976 A1 AR 002976A1
Authority
AR
Argentina
Prior art keywords
formulations
insulin
approximately
long
crystals
Prior art date
Application number
ARP960101937A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR002976A1 publication Critical patent/AR002976A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Se trata de formulaciones parenterales farmacéuticas de efecto prolongado, que comprenden: una suspensión acuosa estéril de aproximadamente 20 U/ml a 500U/ml de un análogo de insulina, aproximadamente 5 mg/ml a aproximadamente 10 mg /ml de cloruros ódico, aproximadamente 0,2 a 2,0 mg/ml de un tampónfisiológicamente aceptable, que contiene aproximadamente de 0,07-0,1 mg/ml de iones zinc y un conservante fisiológicamente aceptable, a un pH del orden de6,5 a 7,8; de modo que al menos 5% delanál ogo presente en la suspensión está disuelto. También se proponen los análogos de insulina cristalizados,utilizables en dichas formulaciones y la preparación de dichos análogos cristalizados.
ARP960101937A 1995-03-31 1996-03-27 Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas AR002976A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41488095A 1995-03-31 1995-03-31

Publications (1)

Publication Number Publication Date
AR002976A1 true AR002976A1 (es) 1998-05-27

Family

ID=23643384

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101937A AR002976A1 (es) 1995-03-31 1996-03-27 Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas

Country Status (23)

Country Link
US (1) US5952297A (es)
EP (1) EP0735048A1 (es)
JP (1) JPH11502856A (es)
KR (1) KR19980703425A (es)
CN (1) CN1185114A (es)
AR (1) AR002976A1 (es)
AU (1) AU720300B2 (es)
BR (1) BR9607935A (es)
CA (1) CA2216516A1 (es)
CO (1) CO4700482A1 (es)
CZ (1) CZ305297A3 (es)
EA (1) EA000970B1 (es)
HU (1) HUP9801700A3 (es)
IL (1) IL117696A (es)
MX (1) MX9707428A (es)
NO (1) NO974498L (es)
NZ (1) NZ305719A (es)
PE (1) PE38797A1 (es)
PL (1) PL322626A1 (es)
TR (1) TR199701078T1 (es)
WO (1) WO1996030040A1 (es)
YU (1) YU18596A (es)
ZA (1) ZA962502B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
SI0884053T1 (en) * 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
US20010007853A1 (en) * 1998-01-08 2001-07-12 Dimarchi Richard Dennis Method for administering monomeric insulin analogs
WO1999048520A1 (en) * 1998-03-24 1999-09-30 Joergensen Klavs Holger Novel preparation of protracted acting human insulin
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CN1125081C (zh) 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd FRAGRANCE COMPOSITION STIMULATING THE SYMPATHETIC SYSTEM
HUP0500733A3 (en) * 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
DK2626368T3 (en) 2004-07-19 2017-02-27 Biocon Ltd INSULIN OLIGOMS CONJUGATES, FORMULATIONS AND APPLICATIONS THEREOF
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
JP5868594B2 (ja) 2007-10-16 2016-02-24 バイオコン・リミテッドBiocon Limited 経口投与可能な固形医薬組成物及びそのプロセス
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
LT3228320T (lt) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND USES THEREOF
NZ594248A (en) 2009-01-28 2015-03-27 Smartcells Inc Conjugate based systems for controlled drug delivery
WO2010092218A2 (es) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2010112358A2 (de) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh Verfahren zur beschichtung einer oberfläche eines bauteils
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
PL3417871T3 (pl) 2009-11-13 2021-06-14 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
EP2504052B1 (en) 2009-11-25 2022-07-27 Boehringer Ingelheim International GmbH Nebulizer
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
DK3139984T3 (da) 2014-05-07 2021-07-19 Boehringer Ingelheim Int Forstøver
WO2015169732A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Container, nebulizer and use
HRP20220596T1 (hr) 2014-05-07 2022-06-24 Boehringer Ingelheim International Gmbh Raspršivač
BR112017000175B1 (pt) * 2014-07-08 2023-11-21 Amphastar Pharmaceuticals,Inc. Método de preparação de uma insulina inalável adequada para a liberação pulmonar e partículas de insulina micronizadas
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
ES2949095T3 (es) 2014-12-12 2023-09-25 Sanofi Aventis Deutschland Formulación de relación fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
US10322168B2 (en) 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
JP2023520049A (ja) 2020-03-31 2023-05-15 プロトマー・テクノロジーズ・インコーポレイテッド 隣接ジオールに対する選択的応答性のためのコンジュゲート
TW202237188A (zh) 2020-11-19 2022-10-01 美商普羅托莫科技公司 芳族含硼化合物及胰島素類似物
US20230374045A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2648622A (en) * 1950-11-29 1953-08-11 Research Corp Purifying insulin by seeding with unclumped fibrils of insulin
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
AT304760B (de) * 1969-08-08 1973-01-25 Novo Terapeutisk Labor As Verfahren zur Reinigung von Insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
AU711428B2 (en) * 1994-06-16 1999-10-14 Eli Lilly And Company Monomeric insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals

Also Published As

Publication number Publication date
NZ305719A (en) 1998-09-24
PE38797A1 (es) 1997-10-04
US5952297A (en) 1999-09-14
CO4700482A1 (es) 1998-12-29
CA2216516A1 (en) 1996-10-03
YU18596A (sh) 1998-07-10
KR19980703425A (ko) 1998-11-05
IL117696A (en) 2000-01-31
PL322626A1 (en) 1998-02-02
CN1185114A (zh) 1998-06-17
HUP9801700A3 (en) 1998-12-28
BR9607935A (pt) 1998-06-02
AU5381296A (en) 1996-10-16
TR199701078T1 (xx) 1998-01-21
NO974498L (no) 1997-10-08
HUP9801700A2 (hu) 1998-11-30
EA199700285A1 (ru) 1998-02-26
ZA962502B (en) 1997-09-29
MX9707428A (es) 1997-12-31
IL117696A0 (en) 1996-07-23
CZ305297A3 (cs) 1998-02-18
EA000970B1 (ru) 2000-08-28
WO1996030040A1 (en) 1996-10-03
JPH11502856A (ja) 1999-03-09
NO974498D0 (no) 1997-09-29
AU720300B2 (en) 2000-05-25
EP0735048A1 (en) 1996-10-02

Similar Documents

Publication Publication Date Title
AR002976A1 (es) Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
AU599792B2 (en) Anti-parkinsonian indolone derivatives
ES2107427T3 (es) Aislamiento de aminoarginina y su uso para bloquear la formacion de oxido nitrico en el cuerpo.
TR200101049T2 (tr) Siklik tetrapeptid bileşiği ve kullanımı
ATE58292T1 (de) L-dopa enthaltendes arzneimittel.
SE8406538D0 (sv) Novel derivatives of purine
BR9708706B8 (pt) composição farmacêutica para administração intravenosa a um paciente
HUT70531A (en) Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
MY102662A (en) Parenteral suspensions
IL103799A (en) Fish production
FI913909A0 (fi) t-PA pro:n stabilointi
US5093348A (en) Pharmaceutical composition for topical ophthalmic use having improved local tolerability
PT98538A (pt) Processo de preparacao de factor de crescimento humano epidermico (hegf) dos seus congeneres e de composicoes farmaceuticas que os contem
NO163133C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv 5r, 6s, 8r-6-(1-hydroxyethyl)-2-(2-carbamoyloxy-ethylthio)-penem-3-carboxylsyre.
US4268518A (en) Method of treating cystitis
HU896426D0 (en) Process for the preparation of aquous solutions of doxorubicin
CA2022323A1 (en) Excretion of potassium ion by prostanoic acid derivatives
IT1273628B (it) Composizioni farmaceutiche per la cura della talassemia contenenti derivati dell'acido butirrico e in particolare isobutirramide
JO1231B1 (en) A way to treat monocytes
JPS6425728A (en) Nootropic (noesis improving agent)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal